NEW YORK (GenomeWeb News) – Sparked by preliminary fourth-quarter revenue results that surpassed analysts' consensus estimate and the launch of its new HiSeq 2000 sequencer, shares of Illumina jumped roughly 20 percent in the month of January.

The firm's stock was the top gainer for the month, followed by Cepheid (+18 percent) and Caliper Life Sciences (+17 percent).

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.